Predictors of long-term outcomes in patients treated with riociguat for chronic thromboembolic pulmonary hypertension: data from the CHEST-2 open-label, randomised, long-term extension trial

• Published in: The lancet respiratory medicine Vol. 4; no. 5; pp. 372 - 380
• Main Authors: Simonneau, Gérald, Prof, D'Armini, Andrea M, Prof, Ghofrani, Hossein-Ardeschir, Prof, Grimminger, Friedrich, Prof, Jansa, Pavel, Prof, Kim, Nick H, Prof, Mayer, Eckhard, Prof, Pulido, Tomas, Prof, Wang, Chen, Prof, Colorado, Pablo, MD, Fritsch, Arno, PhD, Meier, Christian, MD, Nikkho, Sylvia, MD, Hoeper, Marius M, Prof
• Format: Journal Article
• Language: English
• Published: England Elsevier Ltd 01-05-2016
• Subjects: Adult; Aged; Aged, 80 and over; Antihypertensive Agents - administration & dosage; Chronic Disease; Double-Blind Method; Drug Administration Schedule; Female; Humans; Hypertension, Pulmonary - drug therapy; Hypertension, Pulmonary - etiology; Hypertension, Pulmonary - mortality; Male; Middle Aged; Natriuretic Peptide, Brain - blood; Pulmonary Embolism - complications; Pulmonary Embolism - drug therapy; Pulmonary Embolism - mortality; Pulmonary/Respiratory; Pyrazoles - administration & dosage; Pyrimidines - administration & dosage; Time; Treatment Outcome; Young Adult
• ISSN: 2213-2600; 2213-2619
• DOI: 10.1016/S2213-2600(16)30022-4

Summary Background Chronic thromboembolic pulmonary hypertension (CTEPH) is a rare, debilitating, and life-threatening disease. We investigated associations between markers of disease severity and long-term outcomes in patients with inoperable CTEPH or persistent or recurrent pulmonary hypertension after pulmonary endarterectomy (PEA) who were receiving the soluble guanylate cyclase stimulator riociguat. We also present safety and efficacy from the final data cutoff of CHEST-2, where most patients had received riociguat for at least 2 years. Methods Eligible patients from the CHEST-1 study entered the CHEST-2 open-label extension study, in which all patients received riociguat individually adjusted to a maximum dose of 2·5 mg three times per day. The primary endpoint was safety and tolerability. We did exploratory assessments of associations between markers of disease severity (6-min walking distance [6MWD], N-terminal prohormone of brain natriuretic peptide [NT-proBNP] concentration, and WHO functional class) at baseline and follow-up with overall survival and clinical worsening-free survival. We used Kaplan-Meier and Cox proportional hazards analyses. CHEST-2 is registered at ClinicalTrials.gov , number NCT00910429. Findings 237 patients entered CHEST-2. At 2 years, overall survival was 93% (95% CI 89–96) and clinical worsening-free survival was 82% (77–87). A significant association with overall survival was seen for 6MWD and NT-proBNP concentration at baseline (p=0·0199 and p=0·0183, respectively) and at follow-up (p=0·0385 and p=0·0068, respectively). Change from baseline in 6MWD was also significantly associated with survival (p=0·0047). WHO functional class at baseline and follow-up showed no significant association with overall survival but was associated with clinical worsening-free survival. Riociguat was well tolerated by most patients and no new safety signals were identified. Serious adverse events were seen in 129 (54%) of 237 patients, and 14 (6%) discontinued riociguat therapy because of adverse events. Interpretation Riociguat may be used long term in patients with CTEPH. 6MWD and NT-proBNP concentration are good prognostic markers. Funding Bayer Pharma AG.